(CHK, APRI, CRWE, STKL) PennyOmega.com Stocks to Watch

CHK, Chesapeake Energy Corporation
** According to a regulatory filing with the SEC, billionaire investor Carl Icahn holds 50.1 million shares or approximately 7.56% stake in CHK.
CHK is the second-largest producer of natural gas, a Top 15 producer of oil and natural gas liquids and the most active driller of new wells in the U.S.
More about CHK at www.chk.com
********************
APRI, Apricus Biosciences, Inc.
** APRI reported that the Canadian Intellectual Property Office issued a Notice of Allowance for a Canadian patent on certain methods of manufacture for APRI's platform NexACT(R) drug delivery technology.
Specifically, the patent covers the synthesis of Dodecyl 2-(N, N-Dimethylamino)-Propionate (DDAIP) by a transesterification chemical process. DDAIP opens up the tight junctions between cells, allowing drugs to be delivered to the bloodstream.
The patent application (No. 2,706,680), entitled "Crystalline Salts of Dodecyl 2-(N, N-Dimethylamino)-Propionate, is a divisional application of the already issued Canadian Patent No. 2,338,139 bearing the same title and covering crystal salts of DDAIP. When issued, this patent will protect this method of manufacture of DDAIP in Canada, and provides patent exclusivity to May 2020.
The transesterification approach to synthesizing DDAIP represents an advance in the manufacturing process of this technology. The resulting product contains relatively lower levels of by-products and unreacted reactants, which are undesirable and difficult to remove by conventional methods. APRI expects this method to bring significant cost savings for the finished product. This will be the 17th patent granted for this technology worldwide, with two applications pending in this patent family.
In addition, the New Zealand Intellectual Property Office issued a Notice of Acceptance for New Zealand patent application number 576,242, entitled "Stabilized Prostaglandin E Composition," which claims formulations of Vitaros(R), APRI's lead product candidate for the treatment of erectile dysfunction. When issued, this patent will grant exclusive rights to certain pharmaceutical compositions of Vitaros(R)--including its room temperature formulation in New Zealand. It will provide patent exclusivity until October 2027.
Vitaros(R) is a topically delivered formulation of alprostadil combined with APRI's proprietary NexACT(R) delivery technology for the treatment of erectile dysfunction (ED). The NexACT(R) delivery technology enhances the penetration of alprostadil through the skin. When absorbed through the skin, alprostadil, a vasodilator, directly boosts blood flow, thereby causing an erection.
Vitaros(R) differs from oral medications in two ways. First, it is applied locally, directly to the penis as a cream, instead of administered orally and absorbed systemically. This topical application helps to reduce side effects and provides a patient-friendly alternative for men who cannot take the existing oral medications. Second, clinical studies have shown that Vitaros(R) works in approximately 15 minutes on average, compared to a reported onset time of 30 minutes, or longer, for oral medications.
APRI is a pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.
More about APRI at www.apricusbio.com
********************
STKL, SunOpta Inc.
** STKL reported that it has signed a definitive agreement to sell its Canadian natural health products distribution business (operated as Purity Life Natural Health Products) to an affiliate of Banyan Capital Partners.
The transaction, valued at CDN $14,700,000, before transaction costs, is subject to certain conditions and pre-closing matters and is expected to close early in June, 2012.
STKL is a leading global company focused on natural, organic and specialty foods products. The company specializes in sourcing, processing and packaging of natural and organic food products, integrated from seed through packaged products; with a focus on strategically vertically integrated business models.
More about STKL at www.sunopta.com
********************

Internet has become a major medium for communication, entertainment and is in the process of replacing traditional entertainment, promo products, and informative medias.
Internet has also become a major and effective medium for advertising and it has be predicted that the online advertising and marketing is soon going to replace the advertising through traditional medias such as television, radio, newspaper and magazines.
Crown Equity Holdings Inc., (CRWE.OB) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWE's advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
CRWE's division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.
More about CRWE at www.crownequityholdings.com.
********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

CLDX, Celldex Therapeutics, Inc.
ATAI, ATA Inc.
FTI, FMC Technologies, Inc.